Application
Anti-Phospho-KDR/FLK1-Y996 Pab is used in Western blot to detect Phospho-KDR/FLK1-Y996 in HMVEC cell line lysate.Endothelial cells were stimulated with 50ug/ml VEGF for 5min; 20ug lysate from HMVEC was loaded onto an 8% gel; for Western blot, membranes were incubated O/N with Phospho-KDR/FLK1-Y996 Antibody (AP3107a)diluted to 1:500 in 1% Milk/TBST.Data and Protocol kindly provided by Dr. Weis from Cheresh Lab, UCSD.Application
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.| Product Name | Phospho-KDR/FLK1-Y996 Antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Modification | p-Y996 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:100~500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | FLK1, VEGFR2 |
|---|---|
| Alternative Names | KDR FLK1 VEGFR2 Vascular endothelial growth factor receptor 2 Fetal liver kinase 1 Kinase insert domain receptor Protein-tyrosine kinase receptor flk-1 CD_antigen=CD309 Flags: Precursor |
| Molecular Weight(MW) | 151527 Da |
| Function | Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4 Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC |
| Tissue Specificity | Detected in cornea (at protein level). Widely expressed |
| Cellular Localization | Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus Isoform 3: Secreted. |
| Entrez Gene | 3791 |
|---|
Application
Anti-Phospho-KDR/FLK1-Y996 Pab is used in Western blot to detect Phospho-KDR/FLK1-Y996 in HMVEC cell line lysate.Endothelial cells were stimulated with 50ug/ml VEGF for 5min; 20ug lysate from HMVEC was loaded onto an 8% gel; for Western blot, membranes were incubated O/N with Phospho-KDR/FLK1-Y996 Antibody (AP3107a)diluted to 1:500 in 1% Milk/TBST.Data and Protocol kindly provided by Dr. Weis from Cheresh Lab, UCSD.
Application
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.| Application Notes | WB:1:100~500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is first purified by protein G affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with control and phosphorylated peptides. The phospho-specific antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
